ADP-A2AFP

Overview

Overview

Our ADP-A2AFP SPEAR T-cell product targets alpha-fetoprotein (AFP). The Phase 1 clinical trial investigating this product for the treatment of patients with hepatocellular carcinoma (liver cancer) has been closed to enrollment. The Company continues to develop new cell therapies targeting liver cancer.

Our Trials

Our Trials

Cancer indications in the ADP-A2AFP trial

Hepatocellular Cancer

Hepatocellular Cancer

Hepatocellular carcinoma makes up 80% of all cases of liver cancer.

Learn More

Publications

Review our findings and publications.

Latest News

Data update from our ADP-A2AFP Phase 1 trial for liver cancer at ILCA showing clinical benefit.

View Press Release